Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Overlapping kinetochore targets of CK2 and Aurora B kinases in mitotic regulation

CK2 associates with kinetochore protein Mif2/CENP-C. Loss of CK2 results in defects in chromosome segregation, short mitotic spindle, and activation of the spindle assembly checkpoint. CK2 phosphorylates Mif2 and Ndc10. CK2 phosphorylation plays antagonistic and synergistic roles with Aurora B phosphorylation of Mif2 and Ndc10, respectively

Nonlinear Optics

This chapter provides a brief introduction into the basic nonlinear-optical phenomena and discusses some of the most significant recent advances and breakthroughs in nonlinear optics, as well as novel applications of nonlinear-optical processes and devices. Nonlinear optics is the area of optics that studies the interaction of light with matter in the regime where the response of the material system to the applied electromagnetic field is nonlinear in the amplitude of this field. At low light intensities, typical of non-laser sources, the properties of materials remain independent of the intensity of illumination. The superposition principle holds true in this regime, and light waves can pass through materials or be reflected from boundaries and interfaces without interacting with each other. Laser sources, on the other hand, can provide sufficiently high light intensities to modify the optical properties of materials. Light waves can then interact with each other, exchanging momentum and energy, and the superposition principle is no longer valid. This interaction of light waves can result in the generation of optical fields at new frequencies, including optical harmonics of incident radiation or sum- or difference-frequency signals